In the Claims

1. (Currently Amended) A compound represented by Formula (I) or (II):



(I)

or



(II)

or a pharmaceutically acceptable salt thereof, wherein
HET-1 is one of the following heterocycles:



HET-2 is one of the following heterocycles:



R^1 is:

(a) H;

(b) C_1-C_6-alkyl, C_2-C_4-alkenyl, C_2-C_4-alkynyl,C_1-C_6-cycloalkyl, or C_1-C_4-alkyl-[C_1-C_6-cycloalkyl], any of which is optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, S(O)$_{0-2}$-(C_1-C_4)alkyl, O-CONR^{a}R^b, NR^{a}R^b, N(R^a)CONR^{a}R^b, COO-(C_1-C_4)alkyl, COOH, CN, CONR^{a}R^b, SO_2NR^{a}R^b, N(R^a)SO_2NR^{a}R^b, -C(=NH)NH_2, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(c) -O- C_1-C_6-alkyl, -O-C_1-C_6-cycloalkyl, -S-C_1-C_6-alkyl or -S-C_1-C_6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, S(O)$_{0-2}$-(C_1- C_4)alkyl, O-CONR^{a}R^b, NR^{a}R^b, N(R^a)CONR^{a}R^b, COO-(C_1-C_4)alkyl, COOH, CN, CONR^{a}R^b, SO_2NR^{a}R^b, N(R^a)SO_2NR^{a}R^b, -C(=NH)NH_2, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;

(d) -C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl, or -O-C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl;

(e) -OH;

(f) -O-aryl, or –O-C_1-C_4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –C(=O)(R^a), v) -OR^a, vi) -NR^{a}R^b, vii) -C_{0-4}alkyl-CO-OR^a, viii) -(C_{0-4}alkyl)-NH-CO-OR^a, ix) -(C_{0-4}alkyl)-CO-N(R^a)(R^b), x) -S(O)$_{0-2}$R^a, xi) -SO_2N(R^a)(R^b), xii) -NR^aSO_2R^a, xiii) -C_{1-10}alkyl, and xiv) -C_{1-10}alkyl,wherein one or more of the alkyl carbons can be replaced by a -NR^a-, -O-, -S(O)$_{1-2}$-, -O-C(O)-, -C(O)-

O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C- ;

(g) -OCON(R^a)(R^b), or -OSO_2N(R^a)(R^b);

(h) -SH, or -SCON(R^a)(R^b);

(i) NO_2;

(j) NR^aR^b, -N(COR^a)R^b, -N(SO_2R^a)R^b, -N(R^a)CON(R^a)$_2$, -N(R^a)$CONH_2$, -N(OR^a)$CONR^aR^b$, -N(R^a)CON(R^a)$_2$, or -N(R^a)SO_2N(R^a)$_2$;

(k) -CH(OR^a)R^a, -C(OR^b)CF_3, -CH(NHR^b)R^a, -C(=O)R^a, C(=O)CF_3, -$SOCH_3$, -SO_2CH_3, -N(R^a)SO_2R^a, $COOR^a$, CN, $CONR^aR^b$, -COCONR^{a}R^b, -$SO_2NR^aR^b$, -CH_2O-$SO_2NR^aR^b$, SO_2N(R^a)OR^a, -C(=NH)NH_2, -CR^a=N-OR^a, CH=CH$CONR^aR^b$, $CONR^a$, $CONHR^a$;

(l) -$CONR^a(CH_2)_{0-2}C(R^a)(R^b)(CH_2)_{0-2}CONR^aR^b$;

(m) tetrazolyl, tetrazolinonyl, triazolyl, triazolinonyl, imidazolyl, imidozolonyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrazolonyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, or phenyl, any of which is optionally substituted with 1-3 independent substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) -C(=O)R^a, v) C_1-C_6-alkyl , vi) -O-R^a, vii) -NR^aR^b , viii) - C_0-C_4-alkyl -CO-O R^a, ix) -(C_0-C_4-alkyl)-NH-CO-OR^a, x) -(C_0-C_4-alkyl)-CO-NR^a R^b, xi) –S(O)$_{0-2}R^a$, xii) -$SO_2NR^aR^b$, xiii) -$NHSO_2R^a$, xiv) –C_1-C_4-perfluoroalkyl, and xv) –O-C_1-C_4-perfluoroalkyl;

(n) -C(R^a)=C(R^b)-$COOR^a$, or -C(R^a)=C(R^b)-$CONR^aR^b$;

(o) piperidin-1-yl, morpholin-4-yl, pyrrolidin-1-yl, piperazin-1-yl or 4-susbstituted piperazin-1-yl, any of which is optionally substituted with 1-3 substituents selected from



i) -CN, ii) -C(=O)(R^a), iii) C_1-C_6-alkyl , iv) -OR^a, v) -NR^aR^b, vi) -C_0-C_4-alkyl-CO-OR^a, vii) -(C_0-C_4-alkyl)-NH-CO-OR^a, viii) -(C_0-C_4-alkyl)-CON(R^a)(R^b), ix) -SR^a, x) -S(O)$_{0-2}R^a$, xi) -SO_2N(R^a)(R^b), xii) -$NR^aSO_2R^a$ xiii) -C_1-C_4-perfluoroalkyl and xiv) -O-C_1-C_4-perfluoroalkyl;

R^a is

(a) H;

(b) C_1-C_4-alkyl, optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, S(O)$_{0-2}$-(C_1-C_4)alkyl, -$OCONH_2$, -OCONH(C_1-C4alkyl), -OCON(C_1-C4alkyl)(C_1-C4alkyl), -OCONH(C_1-C4alkyl-aryl), -OCON(C_1-C4alkyl)(C_1-C4alkyl-aryl), NH_2, NH(C_1-C4alkyl), N(C_1-C4alkyl)(C_1-C4alkyl), NH(C_1-C4alkyl-

aryl), N(C_1-C4alkyl)(C_1-C4alkyl-aryl), $NHCONH_2$, NHCONH(C_1-C4alkyl), NHCONH(C_1-C4alkyl-aryl), -NHCON(C_1-C4alkyl)(C_1-C4alkyl), NHCON(C_1-C4alkyl)(C_1-C4alkyl-aryl), N(C_1-C4alkyl)CON(C_1-C4alkyl)(C_1-C4alkyl), N(C_1-C4alkyl)CON(C_1-C4alkyl)(C_1-C4alkyl-aryl), COO-(C_1-C4-alkyl), COOH, CN, $CONH_2$, CONH(C_1-C4alkyl), CON(C_1-C4alkyl)(C_1-C4alkyl), SO_2NH_2, SO_2NH(C_1-C4alkyl), SO_2NH(C_1-C4alkyl-aryl), SO_2N(C_1-C4alkyl)(C_1-C4alkyl), $NHSO_2NH_2$, -C(=NH)NH_2, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl or piperazinyl;
(c) C_0-C4-alkyl-(C_1-C4)-perfluoroalkyl; or
(d)C_1-C4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) $-NO_2$, iv) –C(=O)(C_1-C4-alkyl), v) -O(C_1-C4-alkyl), vi) -N(C_1-C4-alkyl)(C_1-C4-alkyl), vii) -C_{1-10}alkyl, and viii) -C_{1-10}alkyl,wherein one or more of the alkyl carbons can be replaced by a , - O-, -S(O)$_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C- ;

R^b is
(a) H; or
(b) C_1-C_6-alkyl, optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C4)alkyl, S(O)$_{0-2}$-(C_1-C4)alkyl, $-OCONH_2$, -OCONH(C_1-C4alkyl), NH_2, NH, NH(C_1-C4alkyl), N(C_1-C4alkyl), N(C_1-C4alkyl)(C_1-C4alkyl), $NHCONH_2$, NHCONH(C_1-C4alkyl), -NHCON(C_1-C4alkyl)(C_1-C4alkyl), COO-(C_1-C4-alkyl), COOH, CN, pyridyl, piperidinyl, pyrimidinyl, piperazinyl, $CONH_2$ or (C_1-C4alkyl)$CONH_2$; or
R^a and R^b, together with the N to which they are attached, can form a 5- or 6-membered ring which optionally contains a heteroatom selected from N, O, and S, and wherein said ring is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) $-NO_2$, iv) –C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C_{0-4}alkyl-CO-OR^a, viii) -(C_{0-4}alkyl)-NH-CO-OR^a, ix) -(C_{0-4}alkyl)-CO-N(R^a)(R^b), x) -S(O)$_{0-2}R^a$, xi) $-SO_2N(R^a)(R^b)$, xii) -$NR^aSO_2R^a$, xiii) -C_{1-10}alkyl, and xiv) –O-;

R^2 and R^3 each independently is:
(a) H;

(b) - C_1-C_4-alkyl, or -O-C_1-C_4-alkyl;
(c) -C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl, or -O-C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl; or
(d) CN, N R^a R^b, NO_2, F, Cl, Br, I, OH, OCONR^a R^b, O(C_1-C_4-alkyl)CONR^a R^b ,-OSO_2NR^a R^b, COOR^a , or CONR^a R^b;

R^4 and R^5 each independently is:
(a) H;
(b) -C_1-C_6-alkyl, -C_2-C_6-alkenyl, -C_2-C_6-alkynyl or -C_1-C_6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3, -O-(C_1-C_4)alkyl, CN, -N(R^a)(R^b), -N(R^a)CO-(C_1-C_4)alkyl, COOR^b, CON(R^a)(R^b) and phenyl;
(c) -O-C_0-C_6-alkyl, -O-aryl, or -O-C_1-C_4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –C(=O)(R^a), v) -OR^a, vi) -NR^{a}R^b, vii) -C_0-4alkyl-CO-OR^a, viii) -(C_0-4alkyl)-NH-CO-OR^a, ix) -(C_0-4alkyl)-CO-N(R^a)(R^b), x) -S(O)$_{0-2}$R^a, xi) -SO_2N(R^a)(R^b), xii) -NR^aSO_2R^a, xiii) -C_1-10alkyl, and xiv) -C_1-10alkyl,wherein one or more of the alkyl carbons can be replaced by a -NR^a-, - O-, -S(O)$_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C-;
(d) -C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl, or -O-C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl; or
(e) CN, NH_2, NO_2, F, Cl, Br, I, OH, OCON(R^a)(R^b) O(C_1-C_4-alkyl)CONR^{a}R^b, -OSO_2N(R^a)(R^b), COOR^b, CON(R^a)(R^b), or aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –C(=O)(R^a), v) -OR^a, vi) -NR^{a}R^b, vii) -C_0-4alkyl-CO-OR^a, viii) -(C_0-4alkyl)-NH-CO-OR^a, ix) -(C_0-4alkyl)-CO-N(R^a)(R^b), x) -S(O)$_{0-2}$R^a, xi) -SO_2N(R^a)(R^b), xii) -NR^aSO_2R^a, xiii) -C_1-10alkyl, and xiv) -C_1-10alkyl,wherein one or more of the alkyl carbons can be replaced by a -NR^a-, - O-, -S(O)$_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C; and

R^6, R^7 and R^8 each independently is:
(a) H;
(b) C_1-C_6-alkyl, C_2-C_4-alkenyl, C_2-C_4-alkynyl or C_1-C_6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-

C_4)alkyl, OCON(R^a)(R^b), NR^aR^b, $COOR^a$, CN, $CONR^aR^b$, N(R^a)$CONR^aR^b$, N(R^a)$SO_2NR^aR^b$, $SO_2NR^aR^b$, S(O)$_{0-2}$(C_1-C_4-alkyl), -C(=NH)NH_2, tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, and piperazinyl;

(c) -O- C_1-C_6-alkyl, -O-C_1-C_6-cycloalkyl, -S-C_1-C_6-alkyl or -S-C_1-C_6-cycloalkyl, any of which is optionally substituted with one or more of the following substituents: F, CF_3, OH, O-(C_1-C_4)alkyl, NH_2, NH(C_1-C_4-alkyl), N(C_1-C_4-alkyl)$_2$, COOH, CN, $CONH_2$, CONH(C_1-C_4-alkyl), CONH(C_1-C_4-alkyl)$_2$, SO_2NH_2, SO_2NH(C_1-C_4-alkyl), tetrazolyl, triazolyl, imidazolyl, oxazolyl, oxadiazolyl, isooxazolyl, thiazolyl, furyl, thienyl, pyrazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyrazinyl, phenyl, piperidinyl, morpholinyl, pyrrolidinyl, or piperazinyl;

(d) -C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl, or -O-C_0-C_4-alkyl-C_1-C_4-perfluoroalkyl;

(e) -O-aryl, or -O-C_1-C_4-alkyl-aryl, wherein aryl is phenyl, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C_{0-4}alkyl-CO-OR^a, viii) -(C_{0-4}alkyl)-NH-CO-OR^a, ix) -(C_{0-4}alkyl)-CO-N(R^a)(R^b), x) -S(O)$_{0-2}R^a$, xi) -$SO_2N(R^a)(R^b)$, xii) -$NR^aSO_2R^a$, xiii) -C_{1-10}alkyl, and xiv) -C_{1-10}alkyl,wherein one or more of the alkyl carbons can be replaced by a -NR^a-, - O-, -S(O)$_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C; or

(f) CN, N(R^a)(R^b), NO_2, F, Cl, Br, I, -OR^a, -SR^a, -OCON(R^a)(R^b), -$OSO_2N(R^a)(R^b)$, $COOR^b$, CON(R^a)(R^b), -N(R^a)CON(R^a)(R^b), -N(R^a)$SO_2N(R^a)(R^b)$, -C(OR^b)R^a, -C(OR^a)CF_3, -C(NHR^a)CF_3, -C(=O)R^a, C(=O)CF_3, -$SOCH_3$, -SO_2CH_3, -$NHSO_2$(C_{1-6}-alkyl), -$NHSO_2$-aryl, $SO_2N(R^a)(R^b)$, -$CH_2OSO_2N(R^a)(R^b)$, $SO_2N(R^b)$-OR^a, -C(=NH)NH_2, -CR_a=N-OR_a, CH=CH or aryl, wherein aryl is ~~phenyl~~, pyridyl, pyrimidinyl, furyl, thienyl, pyrrolyl, triazolyl, pyrazolyl, thiazolyl, isoxazolyl, oxazolyl, or oxadiazolyl, any aryl of which is optionally substituted with 1-3 substituents selected from i) F, Cl, Br, I, ii) -CN, iii) -NO_2, iv) –C(=O)(R^a), v) -OR^a, vi) -NR^aR^b, vii) -C_{0-4}alkyl-CO-OR^a, viii) -(C_{0-4}alkyl)-NH-CO-OR^a, ix) -(C_{0-4}alkyl)-CO-N(R^a)(R^b), x) -S(O)$_{0-2}R^a$, xi) -$SO_2N(R^a)(R^b)$, xii) -$NR^aSO_2R^a$, xiii) -C_{1-10}alkyl, and xiv) -C_{1-10}alkyl,wherein one or more of the alkyl carbons can be replaced by a -NR^a-, - O-, -S(O)$_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-N(R^a)-, -N(R^a)-C(O)-, -N(R^a)-C(O)-N(R^a)-, -C(O)-, -CH(OH)-, -C=C-, or -C≡C; or when R^6 and R^7 are present on adjacent carbon

atoms, R^6 and R^7, together with the benzene ring to which they are attached, can form a bicyclic aromatic ring selected from naphthyl, indolyl, quinolinyl, isoquinolinyl, quinoxalinyl. benzofuryl, benzothienyl, benzoxazolyl, benzothiazolyl, and benzimidazolyl, any of which is optionally substituted with 1-4 independent substituents selected from i) halogen, ii) -CN, iii) $-NO_2$, iv) –CHO, v) -O-C_{1-4}alkyl, vi) -N(C_{0-4}alkyl)(C_{0-4}alkyl), vii) -C_{0-4}alkyl-CO-O(C_{0-4}alkyl), viii) -(C_{0-4}alkyl)-NH-CO-O(C_{0-4}alkyl), ix) -(C_{0-4}alkyl)-CO-N(C_{0-4}alkyl)(C_{0-4}alkyl), x) -S(C_{0-4}alkyl), xi) -S(O)(C_{1-4}alkyl), xii) $-SO_2$(C_{0-4}alkyl), xiii) $-SO_2$N(C_{0-4}alkyl)(C_{0-4}alkyl), xiv) $-NHSO_2$(C_{0-4}alkyl)(C_{0-4}alkyl), xv) $-C_{1-10}$alkyl and xvi) $-C_{1-10}$alkyl in which one or more of the carbons can be replaced by a -N(C_{0-6}alkyl)-, -O-, -S(O)$_{1-2}$-, -O-C(O)-, -C(O)-O-, -C(O)-N(C_{0-6}alkyl)-, -N(C_{0-6}alkyl)-C(O)-, -N(C_{0-6}alkyl)-C(O)-N(C_{0-6}alkyl)-, -C(O)-, -CH(OH), -C=C-, or -C≡C-;

with the proviso that compounds of formula I exclude compounds wherein one of R^4 and R^5 is hydrogen and the other is 2-OH and two of R^6, R^7, and R^8 are hydrogen and the other is –OH in the para position;

with the proviso that compounds of formula II exclude compounds wherein HET-1 is



and HET-2 is



at the same time;

and excluding 4-(4-aminophenyl)-6-(4'-methoxybiphenyl-3-yl)pyrimidin-2-amine.

2. (Original) The compound according to Claim 1 represented by Formula (I), or a pharmaceutically acceptable salt thereof.

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Once Amended) The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



8. (Once Amended) The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



9. (Once Amended) The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



10. (Canceled)

11. (Once Amended) The compound according to Claim 2, or a pharmaceutically acceptable salt thereof, wherein

R^6 is other than H and is attached at the ortho position.

12. (Original) The compound according to Claim 1 represented by Formula (II), or a pharmaceutically acceptable salt thereof.

13. (Original) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



14. (Original) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



15. (Original) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



16. (Original) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



17. (Original) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



18. (Original) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



19. (Original) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



20. (Original) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-2 is



21. (Cancelled)

22. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is

 and

HET-2 is



23. (Canceled)

24. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



25. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



26. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



27. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



28. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



29. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



30. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



31. (Once Amended) The compound according to Claim 12, or a pharmaceutically acceptable salt thereof, wherein

HET-1 is



32. (Canceled)

33. (Original) A compound represented by



or a pharmaceutically acceptable salt thereof.

34. (Original) The compound of Claim 1 represented by



R6	R7	R2	R1
OCF_3	H	H	H
OCF_3	H	H	
OCF_3	H	H	$-SCH_3$
OCF_3	H	H	$-SO_2CH_3$
OCF_3	H	H	$-SOCH_3$
OCF_3	H	H	NH_2
OCF_3	H	H	$NHSO_2CH_3$
OCF_3	H	H	$N(SO_2CH_3)2$
OCF_3	H	H	$NHCO(CH_3)_3$
OCF_3	H	H	$CON(CH_3)OCH_3$
OCF_3	H	H	
OCF_3	H	H	CH_3CO
OCF_3	H	H	$CONHC(CH_3)_2COOCH_3$
OCF_3	H	H	$CONHCH_2CH_2CN$
OCF_3	H	H	$CONHC(CH_3)_2COOH$

R^6	R^7	R^2	R^1
OCF_3	H	H	$CONHC(CH_3)_2CONH_2$
OCF_3	H	H	$CON(CH_2CH_2)_2NH$
OCF_3	H	H	
OCF_3	H	H	$CONHC(CH_2)_2COOCH_3$
OCF_3	H	H	$CONHC(CH_2)_2COOH$
OCF_3	H	H	$CONHC(CH_2)_2CONH_2$
OCF_3	H	H	$CON(CH_2)_2N(CH_3)_2$
OCF_3	H	H	$CONHCH_3$
OCF_3	H	H	$CON(CH_3)_2$
OCF_3	H	H	$COOCH_3$
OCF_3	H	H	$CONHCH(CH_3)CONH_2$ (S)
OCF_3	H	H	
OCF_3	H	H	$CONHC(CH_3)_3$
OCF_3	H	H	$CON(CH_3)_2CH_2OH$
OCF_3	H	H	$CONHCH(CH_3)CONH_2$ (R)
OCF_3	H	H	
OCF_3	H	CH_3	CH_3
OCF_3	H	CH_3	COOH
OCF_3	H	CH_3	$CONH_2$
OCF_3	H	H	$CONHCH_2CONH_2$
OCF_3	H	Cl	CH_3
OCF_3	H	Cl	$CONH_2$

R^6	R^7	R^2	R^1
OCF_3	H	H	$NHCONH_2$
CF_3	H	H	CH_3
CF_3	H	H	H
CF_3	H	H	COOH
CF_3	H	H	$CONH_2$
CF_3	H	H	
CF_3	H	H	SH
CF_3	H	H	$S\text{-}COCH_3$
CF_3	H	H	Cl
CF_3	H	H	CN
CF_3	H	H	
CF_3	5-F	H	CH_3
CF_3	5-F	H	COOH
CF_3	5-F	H	$CONH_2$
CF_3	4-F	H	$CONH_2$
CF_3	4-Cl	H	$CONH_2$
Cl	6-Cl	H	$CONH_2$
CF_3	$6\text{-}CF_3$	H	COOH
CF_3	$6\text{-}CF_3$	H	$CONH_2$
CF_3	$4\text{-}CF_3$	H	CH_3
CF_3	$4\text{-}CF_3$	H	COOH

R^6	R^7	R^2	R^1
CF_3	4-CF_3	H	$CONH_2$
CF_3	4-CF_3	H	
O-Ph	H	H	CH_3
O-Ph	H	H	COOH
O-Ph	H	H	$CONH_2$
H	O-Ph	H	$CONH_2$
Cl	H	H	CH_3
H	3-Cl	H	CH_3
-SO_2NH-tBu	H	H	CH_3
-SO_2NH_2	H	H	CH_3
-CONH-tBu	H	H	CH_3
-$CONH_2$	H	H	CH_3
-CONH-tBu	H	H	COOH
-CONH-tBu	H	H	$CONH_2$
Cl	3-Cl	H	COOH
Cl	3-Cl	H	$CONH_2$
Cl	3-Cl	H	$COOCH_3$
-SO_2NH-tBu	H	H	COOH
-SO_2NH_2	H	H	COOH
-SO_2NH-tBu	H	H	$CONH_2$
-SO_2NH_2	H	H	$CONH_2$
OtBu	H	H	CH_3

R6	R7	R2	R1
OtBu	H	H	COOH
OtBu	H	H	$CONH_2$
	H	H	CH_3
	H	H	COOH
	H	H	$CONH_2$
OCH_2CF_3	H	H	CH_3
OCH_2CF_3	H	H	COOH
OCH_2CF_3	H	H	$CONH_2$
CHO	H	H	$CONH_2$
H	3-CF_3	H	$CONH_2$
H	4-CF_3	H	$CONH_2$
H	3-F	H	$CONH_2$
H	4-Cl	H	$CONH_2$
H	4-F	H	$CONH_2$
	H	H	$CONH_2$
OCH_3	3-OCH_3	H	$CONH_2$
OCH_3	5-Cl	H	$CONH_2$
CH_3	H	H	$CONH_2$
CH_3	3-F	H	$CONH_2$
	H	H	$CONH_2$
H	4-(CH_2OH)	H	$CONH_2$

R^6	R^7	R^2	R^1
H	3-Cl	H	$CONH_2$
H	3-OEt	H	$CONH_2$
H	4-OEt	H	$CONH_2$
F	H	H	$CONH_2$
CH_3	6-CH_3	H	$CONH_2$
H	4-tBu	H	$CONH_2$
H	4-OCF_3	H	$CONH_2$
H	4-$COCH_3$	H	$CONH_2$
H	3-$COCH_3$	H	$CONH_2$
H	3-(CH_2OH)	H	$CONH_2$
H	4-CN	H	$CONH_2$
H	3-OCF_3	H	$CONH_2$
F	4-F	H	$CONH_2$
H	H	H	$CONH_2$
OCF_3	4-N(Me)SO_2Me	H	CH_3
OCF_3	4-N(Me)SO_2Me	H	$CONH_2$
OCF_3	4-NHCO-tBu	H	CH_3
OCF_3	4-NHCO-tBu	H	COOH
OCF_3	4-NHCO-tBu	H	$CONH_2$
OCF_3	H	H	
OCF_3	H	H	

R6	R7	R2	R1
OCF_3	H	H	
OCF_3	H	H	
OCF_3	H	H	$-CH_2CONH_2$
OCF_3	H	H	$-CH_2CN$
OCF_3	H	H	$-SO_2NHtBu$
OCF_3	H	H	$-SO_2NH_2$
OCF_3	H	H	$-SO_2NHMe$
OCF_3	H	H	$-CH_2OH$
OCF_3	H	H	-CH(Me)OH
OCF_3	H	H	$-CH_2NHCOCH_3$
OCF_3	H	H	$-CH_2OSO_2NH_2$
OCF_3	H	H	$-NHCH_3$
OCF_3	H	H	$-NH-CH(CH_3)2$
OCF_3	H	H	

or a pharmaceutically acceptable salt thereof.

35. (Original) The compound of Claim 1 represented by



A	R1

	$CONH_2$
	$CONH_2$
	$CONH_2$
	$CONH_2$
	$CONH_2$
	$CONH_2$
	$CONH_2$
	$CONH_2$
	$CONH_2$

or a pharmaceutically acceptable salt thereof.

36. (Original) The compound of Claim 1 represented by



R^6	R^4	R^2	R^1
OCF_3	4-F	H	CH_3
OCF_3	4-F	H	COOH

R^6	R^4	R^2	R^1
OCF_3	4-F	H	$COOCH_3$
OCF_3	4-F	H	$CONH_2$
CF_3	4-F	H	$COOCH_3$
CF_3	4-F	H	$CONH_2$
CF_3	4-F	H	CH_3
OCF_3	2-OCH_2Ph	H	CH_3
OCF_3	2-OH	H	CH_3
OCF_3	4-NHAc	H	CH_3
OCF_3	4-NHAc	H	$COOCH_3$
OCF_3	4-NHAc	H	$CONH_2$
OCF_3	2-F	H	CH_3
OCF_3	2-F	H	$COOCH_3$
OCF_3	2-F	H	$CONH_2$
OCF_3	4-Br	H	CH_3
OCF_3	4-Br	H	$COOCH_3$
OCF_3	4-Br	H	$CONH_2$
OCF_3	4-Br	H	COOH
OCF_3	4-Ph	H	CH_3
OCF_3	4-Ph	H	$COOCH_3$
OCF_3	4-Ph	H	$CONH_2$
OCF_3	4-Cl	H	CH_3
OCF_3	4-Cl	H	$COOCH_3$
OCF_3	4-Cl	H	COOH
OCF_3	4-Cl	H	$CONH_2$
OCF_3	2-Cl	H	CH_3
OCF_3	2-Cl	H	$COOCH_3$
OCF_3	2-Cl	H	$CONH_2$
OCH_2CF_3	4-F	H	CH_3
OCH_2CF_3	4-F	H	$COOCH_3$
OCH_2CF_3	4-F	H	COOH
OCH_2CF_3	4-F	H	$CONH_2$
H	4- OCH_2CF_3	H	$CONH_2$

R^6	R^4	R^2	R^1
OCF_3	4-F	CH_3	CH_3
OCF_3	4-F	CH_3	$COOCH_3$
OCF_3	4-F	CH_3	$CONH_2$
F	4- OCH_2CF_3	H	$CONH_2$

or a pharmaceutically acceptable salt thereof.

37. (Currently Amended) The compound of Claim 1 represented by



R^6	R^{21}
CF_3	CH_3
CF_3	COOH
CF_3	$CONH_2$
OCF_3	CH_3
OCF_3	COOH
OCF_3	$CONH_2$

or a pharmaceutically acceptable salt thereof.

38. (Original) A compound represented by



		

or a pharmaceutically acceptable salt thereof.

39. (Original) The compound of Claim 1 represented by



R6	R1
OCF_3	CH_3
OCF_3	COOH
OCF_3	$COOCH_3$
OCF_3	$CONH_2$

or a pharmaceutically acceptable salt thereof.

40. (Original) The compound of Claim 1 represented by



R6	R1
OCF_3	CH_3
OCF_3	COOH
OCF_3	$CONH_2$
CF_3	CH_3
CF_3	COOH
CF_3	$CONH_2$

or a pharmaceutically acceptable salt thereof.

41. (Canceled)

42. (Canceled)

43. (Original) A compound represented by



or a pharmaceutically acceptable salt thereof.

44. (Original) A pharmaceutical composition comprising a therapeutically effective amount of the compound according to Claim 1, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

45. (Once Amended) The pharmaceutical composition according to Claim 44, further comprising a second therapeutic agent selected from the group consisting of: i) opiate agonists, ii) opiate antagonists, iii) calcium channel antagonists, iv) 5HT receptor agonists, v) 5HT receptor antagonists vi) sodium channel antagonists, vii) NMDA receptor agonists, viii) NMDA receptor antagonists, ix) COX-2 selective inhibitors, x) NK1 antagonists, xi) non-steroidal anti-inflammatory drugs, xii) selective serotonin reuptake inhibitors, xiii) selective serotonin and norepinephrine reuptake inhibitors, xiv) tricyclic antidepressant drugs, xv) norepinephrine modulators, xvi) lithium, xvii) valproate, and xviii) neurontin.

46. (Canceled)

47. (Canceled)

48. (Canceled)

49. (Canceled)

50. (Canceled)

51. (Canceled)

52. (Canceled)

53. (Canceled)

54. (Canceled)

55. (Canceled)

56. (Canceled)

57. (Canceled)

58. (Canceled)